Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC, Nov. 9, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has executed a binding letter of intent (“LOI“) with REVITALIST LIFESTYLE AND WELLNESS LTD.

Source

Previous articleNova Mentis Files Genetic Neuroinflammatory Disease Patent
Next articleCOMPASS Pathways plc announces financial results and business highlights for the third quarter 2021